Biotinylated Human CD8 alpha / CD8A Protein, His,Avitag?
分子別名(Synonym)
CD8A,CD8,Leu2,MAL,p32
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Biotinylated Human CD8 alpha, His,Avitag (CDA-H82E3) is expressed from human 293 cells (HEK293). It contains AA Ser 22 - Asp 182 (Accession # P01732-1).
Predicted N-terminus: Ser 22
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 21.2 kDa. The protein migrates as 25-32 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
標(biāo)記(Labeling)
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
在免疫反應(yīng)中起重要作用的完整膜糖蛋白,在抵抗外部和內(nèi)部攻擊的反應(yīng)中具有多種功能。同時與T細(xì)胞受體(TCR)和抗原呈遞細(xì)胞(APC)呈遞的MHC I類蛋白相互作用。反過來,Src激酶LCK被募集到TCR-CD3復(fù)合物附近。在NK細(xì)胞中,細(xì)胞表面CD8A同源二聚體的存在提供了一種存活機(jī)制,允許多個靶細(xì)胞的結(jié)合和裂解。CD8A同二聚體分子還促進(jìn)活化淋巴細(xì)胞的存活和分化為記憶性CD8 T細(xì)胞。
關(guān)鍵字: CD8 alpha;CD8 alpha蛋白;CD8A重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。